Company intelligence / Profile preview

Vivici

Delft, Netherlands

Ownership: Private
Development stage: Other

Overview

Vivici commercializes precision-fermented animal-free dairy proteins, with its first product, Vivitein BLG, launched in the US and focusing on superior nutrition and sustainability; additional launches, including lactoferrin, are planned for 2025. Their first products have achieved regulatory milestones (self-affirmed GRAS in the US) and initial offtake agreements; large-scale clinical or nutritional trial results are not publicly described as of October 2025.

Modalities: ProteinRecombinant protein
Industry: Food & Nutrition

Partnerships

dsm-firmenichFonterra

Beyond the preview

Go deeper on Vivici.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivici.

Explore the full profile